Tevimbra (Tislelizumab-jsgr) sold under the brand name 百泽安 in china, is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.
Chinese Version
Brand name：Tevimbra (百泽安)
INN name：Tislelizumab (替雷利珠单抗)
Manufacturer：BeiGene Biotechnology (百济神州)
Packaging：10ml*100mg/Box
Inquire&E-mail: care@100pei.com
The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
扫一扫 
